Stocks · Health care · Biological Products, (No Diagnostic Substances)

aTYR PHARMA INC

ATYR Clue Score30
United States Fiscal year ends December CIK 0001339970 Results filed 5 Nov 2026

What the insiders did Net buying

Insider
Date
Role
Action
Shares
Price
Amount
Paul Schimmel
27 May 2026
Director
Buy indirect
100,000
$0.50
$49.63K
Paul Schimmel
9 Oct 2025
Director
Buy indirect
317,999
$0.94
$299.36K
Paul Schimmel
8 Oct 2025
Director
Buy indirect
682,001
$0.90
$612.44K
Jane A Gross
17 Mar 2025
Director
Buy
3,750
$4.00
$15.00K
Paul Schimmel
24 Jul 2024
Director
Buy indirect
52,300
$1.93
$101.04K
Paul Schimmel
23 Jul 2024
Director
Buy indirect
6,648
$1.82
$12.07K
Paul Schimmel
22 Jul 2024
Director
Buy indirect
41,052
$1.74
$71.50K
Nancy Denyes
5 Jun 2024
General Counsel
Buy
5,000
$1.86
$9.28K
Sanjay Shukla
31 May 2024
President and CEO
Buy
20,000
$1.81
$36.14K
Jill Marie Broadfoot
31 May 2024
Chief Financial Officer
Buy
5,000
$1.79
$8.95K
Timothy Coughlin
30 May 2024
Director
Buy indirect
50,000
$1.75
$87.50K
Sanjay Shukla
12 Dec 2023
President and CEO
Buy
12,000
$1.18
$14.14K
Sanjay Shukla
11 Dec 2023
President and CEO
Buy
3,000
$1.17
$3.51K
Sanjay Shukla
13 Nov 2023
President and CEO
Buy
13,578
$1.11
$15.09K
Sanjay Shukla
10 Nov 2023
President and CEO
Buy
1,422
$1.14
$1.62K
Sanjay Shukla
28 Jul 2023
President and CEO
Buy
15,000
$2.01
$30.22K
Paul Schimmel
10 May 2023
Director
Buy indirect
200,000
$2.25
$450.00K
Sanjay Shukla
21 Nov 2022
President and CEO
Buy
10,000
$2.14
$21.41K
Sanjay Shukla
1 Jul 2022
President and CEO
Buy
15,000
$2.88
$43.16K
Jill Marie Broadfoot
13 Jan 2022
Chief Financial Officer
Buy
1,923
$6.75
$12.98K
Sanjay Shukla
7 Jan 2022
President and CEO
Buy
5,000
$6.76
$33.81K
Sanjay Shukla
15 Nov 2021
President and CEO
Buy
2,500
$8.58
$21.44K
Paul Schimmel
20 Sep 2021
Director
Buy
250,000
$8.00
$2.00M
Sanjay Shukla
18 May 2021
President and CEO
Buy
10,000
$4.01
$40.10K
Paul Schimmel
18 May 2021
Director
Buy indirect
50,000
$3.98
$199.00K
Sanjay Shukla
19 Jun 2020
President and CEO
Buy
6,000
$4.27
$25.62K
Jill Marie Broadfoot
19 Jun 2020
Chief Financial Officer
Buy
1,850
$4.22
$7.81K
Paul Schimmel
10 Feb 2020
Director
Buy indirect
254,000
$4.25
$1.08M
John Mendlein
21 Dec 2018
Director
Buy
195,000
$0.42
$82.60K
John Mendlein
20 Dec 2018
Director
Buy
50,000
$0.41
$20.65K
Paul Schimmel
26 Nov 2018
Director
Buy indirect
147,225
$0.54
$79.80K
Jill Marie Broadfoot
20 Sep 2018
Chief Financial Officer
Buy
38,000
$0.84
$31.74K
Jill Marie Broadfoot
19 Sep 2018
Chief Financial Officer
Buy
26,000
$0.81
$21.12K
Jill Marie Broadfoot
14 Sep 2018
Chief Financial Officer
Buy
26,000
$0.73
$19.06K
Paul Schimmel
4 Sep 2018
Director
Buy indirect
20,749
$0.76
$15.71K
Paul Schimmel
31 Aug 2018
Director
Buy indirect
22,000
$0.72
$15.75K
Paul Schimmel
30 Aug 2018
Director
Buy indirect
89,275
$0.76
$67.48K
Paul Schimmel
29 Aug 2018
Director
Buy indirect
75,136
$0.72
$54.09K
Paul Schimmel
18 May 2018
Director
Buy indirect
150,000
$1.00
$149.45K
EcoR1 Capital Fund Qualified, L.P.
1 Nov 2017
10% owner
Buy
24,728
$4.80
$118.69K
EcoR1 Capital Fund Qualified, L.P.
1 Oct 2017
10% owner
Buy
4,879
$5.05
$24.64K
John Mendlein
31 Aug 2017
CEO and Director
Buy
37,736
$2.65
$100.00K
Paul Schimmel
31 Aug 2017
Director
Buy indirect
94,336
$2.65
$249.99K
John Mendlein
24 Apr 2017
CEO and Director
Buy
124
$3.00
$372.00
John Mendlein
20 Apr 2017
CEO and Director
Buy
1,552
$3.00
$4.66K
John Mendlein
18 Apr 2017
CEO and Director
Buy
1,000
$3.00
$3.00K
Paul Schimmel
21 Dec 2016
Director
Buy indirect
10,000
$2.28
$22.82K
Ashraf Amanullah
20 Dec 2016
Vice President, Manufacturing
Buy
11,000
$2.25
$24.75K
Paul Schimmel
20 Dec 2016
Director
Buy indirect
15,000
$2.27
$34.11K
John Mendlein
19 Dec 2016
CEO and Director
Buy
69,000
$2.20
$151.66K
Paul Schimmel
16 Dec 2016
Director
Buy indirect
10,000
$2.40
$23.97K
Paul Schimmel
15 Dec 2016
Director
Buy indirect
40,000
$2.50
$99.91K

What was left out

Form 4 filings counted 183
Amendments (4/A) skipped 2
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 28
Transactions with no price 0
Shares from compensation/vesting 2,492,427
Sales filed before the plan box existed 22
History held since 8 May 2015